Invetus’ Dr Elizabeth Evans attended the BIO-Europe 2018 partnering event recently, with the objective of increasing Invetus’ profile as a partner in pre-clinical drug development.
One of the opportunities Invetus has identified is providing pre-clinical research services to companies developing medicines or devices for human use.
At the BIO-EUROPE meeting in Berlin last year, there were 4,000 attendees from 61 countries, representing nearly 2,200 companies. Connecting with potential partners, as well as pitching new business opportunities are key reasons to attend, and the three-day meeting is usually jam-packed with both presentations and plenary sessions, as well as a myriad of partnering meetings – over 24,000 of them last year.
In Copenhagen, Invetus has partnered with GreenLight Clinical, since together we offer overseas or local drug/device developers a one-stop-shop for their R&D program.
Invetus can access a range of large animal models of disease for pre-clinical studies, which are often more effective than rodent models for predicting human safety and toxicity.
GreenLight Clinical is a full service contract research organisation, who offer a range of research services across all phases of development.
Liz commented “it has been immensely stimulating meeting people from all over the world, who are so excited about their development candidate. I am quietly confident that Invetus will acquire new business as result of the networking and partnering meetings here.”